I B kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia

Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

(2010) S. M. Kornblau et al.   CLINICAL CANCER RESEARCH

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia

(2009) J. Tamburini et al.   BLOOD

A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer

(2009) J.-Y. Yang et al.   CLINICAL CANCER RESEARCH

High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

(2009) Carlos M. Santamaría et al.   LEUKEMIA RESEARCH

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

(2008) S Park et al.   LEUKEMIA

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

(2008) Jer-Yen Yang et al.   NATURE CELL BIOLOGY

Structure/function relationships underlying regulation of FOXO transcription factors

(2008) T Obsil et al.   ONCOGENE

Deregulation of Signaling Pathways in Acute Myeloid Leukemia

(2008) Claudia Scholl et al.   SEMINARS IN ONCOLOGY